EMEA-000181-PIP02-13-M01 - paediatric investigation plan

Cannabidiol
delta-9-tetrahydrocannabinol
PIPHuman

Key facts

Invented name
Sativex
Active Substance
  • Cannabidiol
  • delta-9-tetrahydrocannabinol
Therapeutic area
Pain
Decision number
P/0373/2022
PIP number
EMEA-000181-PIP02-13-M01
Pharmaceutical form(s)
Oromucosal spray
Condition(s) / indication(s)
Treatment of pain
Route(s) of administration
Oromucosal use
Contact for public enquiries

GW Pharma Ltd

United Kingdom
Tel. +44 (0)1223 266800
E-mail: medinfo@gwpharm.com

Decision type
PM: decision on the application for modification of an agreed PIP
Decision date

Decision

Share this page